Inactive Instrument
Anacor Pharmaceuticals Inc Stock
Stocks
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16-05-26 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 16-05-16 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 79 | 2004-01-31 | |
Margaret Madden
PRN | Corporate Officer/Principal | - | 2016-06-23 |
| General Counsel | 77 | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Madden
BRD | Director/Board Member | - | 2016-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 2016-06-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.81% | +27.25% | +80.21% | 60.14B | |
| -2.54% | -1.65% | +4.86% | +33.32% | 48.15B | |
| -2.93% | -4.70% | +28.62% | +35.19% | 44.25B | |
| +0.94% | +3.48% | +350.96% | +690.26% | 43.99B | |
| -1.76% | -0.25% | +7.14% | +101.17% | 41.61B | |
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -3.68% | -9.74% | -25.51% | +332.44% | 24.93B | |
| Average | +0.19% | +1.97% | +54.51% | +160.09% | 44.09B | |
| Weighted average by Cap. | +0.35% | +1.83% | +58.79% | +151.37% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
